Adagio Medical Holdings, Inc. - 8-K Filing
Adagio Medical Holdings, Inc. reported first-quarter financial results for the quarter ended March 31, 2026, with a net loss of $7.0 million compared to $7.7 million in the same period last year. The company also announced significant clinical progress including late-breaking data from its FULCRUM-VT trial showing 84% freedom from ICD shock at six months and received FDA approval to expand this trial for a next-generation ablation system. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $ADGM